As a prophylaxis in COVID-19 era

℞ ViBact-DS

(Bacillus Mesentericus – 2 million, Clostridium Butyricum – 4 million, Streptococcus Faecalis – 60 million, Lactobacillus Sporogenes – 100 million)

Synergistic combination of Pre-Probiotic

Probiotics has Prophylactic and Supportive therapeutic role in the management of COVID-19

Gut dysbiosis is common in COVID-19



Prophylactic Role of Probiotics

- Helps to preserve intestinal balance and reduces dysbiosis[1]
- Improves gut & lung immunity by gut-lung axis[2]
- Reduces the incidences of acute respiratory infections in elderly population[3]

Supportive Therapeutic Role of Probiotics

- Helps to prevent secondary bacterial infections[1]
- Helps to reduce inflammatory responses[1]

ARDS: Acute Respiratory Distress Syndrome

1. Transl Res. 2020 Dec; 226: 57–69 2. Appl Microbiol Biotechnol. 2020 Aug 19 : 1–16. 3. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD006895

As a prophylaxis in COVID-19 era

Rx ViBact-DS

(Bacillus Mesentericus – 2 million, Clostridium Butyricum – 4 million, Streptococcus Faecalis – 60 million, Lactobacillus Sporogenes – 100 million)

Synergistic combination of Pre-Probiotic

Antibiotic burden & related diarrhea during COVID-19 pandemic

Only 8%
of COVID-19 patients developed hospital-acquired bacterial or fungal infections;
But
72% received antibiotic treatment[1]

"Antibiotics and antivirals are often used for COVID-19 treatment, involving a likely alteration of the gut microbiota causing diarrhea"[3]

40% of severe COVID 19 patients have reported Diarrhea incidences[2]

Pre-probiotic combination reduces Antibiotic Associated Diarrhea by[2]

1. The economic times health world, July 9, 2020, https://health.economictimes.indiatimes.com/news/industry/the-need-to-address-amr-burden-during-covid-19-times/76868511 2. Transl Res. 2020 Dec; 226: 57–69 3. Clin Gastroenterol Hepatol. 2020 Jul; 18(8): 1663–1672.
4. J Clin Gastronenterol 2011;45;S149-S153,

In C. difficile-associated diarrhea

℞ ViBact-DS

(Bacillus Mesentericus – 2 million, Clostridium Butyricum – 4 million, Streptococcus Faecalis – 60 million, Lactobacillus Sporogenes – 100 million)

Synergistic combination of Pre-Probiotic

Probiotics for prevention and treatment of C. difficile-associated diarrhea (CDAD)

25%
of antibiotic-associated diarrhea is caused by **Clostridium difficile**[1]

➤

Meta - analysis of **31 RCTs** including **8672 patients**[1]

➤

Probiotics supplementations with antibiotics reduce the risk of **CDAD** by[1]

1 Arch Intern Med. 2001;161(4):525-533 Cochrane Database Syst Rev. 2017 Dec; 2017(12): RCT: Randomized Controlled Trial

Co-Rx along with Antihypertensives & Antidiabetics

℞ ViBact-DS

(Bacillus Mesentericus – 2 million, Clostridium Butyricum – 4 million, Streptococcus Faecalis – 60 million, Lactobacillus Sporogenes – 100 million)

Synergistic combination of Pre-Probiotic

Role of Probiotics in Chronic Disorders

Role of Probiotics in Hypertension

- Balances Na^+ Metabolism[1]
- Enhances Vasodilation[1]
- Balances F/B ratio[1]

Role of Probiotics in Diabetes

- Alleviates GI side effects of OADs[1]
- Reduces FPG by 15.92 mg/dl[1]
- Reduces HbA1c by 0.81%[1]

1 Cap OD



1 Arch Intern Med. 2001;161(4):525-533
Cochrane Database Syst Rev. 2017 Dec; 2017(12):

℞ ViBact-DS

(Bacillus Mesentericus – 2 million, Clostridium Butyricum – 4 million, Streptococcus Faecalis – 60 million, Lactobacillus Sporogenes – 100 million)

Synergistic combination of Pre-Probiotic

Prebiotic:
Genetically Modified
Bacillus Mesentericus (GMBM)

Probiotic:
Clostridium
Butyricum



Probiotic:
Streptococcus
Faecalis

Probiotic:
Lactobacillus
Sporogenes

GMBM rapidly multiplies probiotics as compared to other prebiotics[1]



Benefits of Vibact DS

- Can withstand gastric acid pH as low as 1.2[1]
- Promotes the growth of Bifidobacterium species[2]
- Improves stool consistency and frequency in diarrhea[3]
- Stimulates the mucosal immunity[4]

•Data on file GIT- Gastrointestinal Tract

1. Br. J Nutr (1998) 80 Suppl S 147- S171 2. Microbios. 2000;101(399):105-14. 3. Scientific Reports | (2018) 8:2964 | DOI:10.1038/s41598-018-21241-z
4. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 2018, VOL. 58, NO. 10, 1660–1670